TELO (Telomir Pharmaceuticals) ROE % Adjusted to Book Value: -8.07% (As of Mar. 2026)


TELO Telomir Pharmaceuticals Inc TELO
14 GF Score
Price $1.27
! 3 Warning Signs
View Full Analysis

What is Telomir Pharmaceuticals ROE % Adjusted to Book Value?

Telomir Pharmaceuticals TELO -3.79% 14 ROE % Adjusted to Book Value is -8.07% as of Mar. 2026. GuruFocus rates TELO with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Telomir Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -72.90%. Telomir Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 9.03. Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -8.07%.

Telomir Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Telomir Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Telomir Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals ROE % Adjusted to Book Value Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -4.33 -41.09

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -162.23 -17.51 -16.54 -8.07

TELO vs MAIA, LONA, CRDF: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Telomir Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's ROE % Adjusted to Book Value falls into.


TELO
14GF Score
Telomir Pharmaceuticals Inc TELO
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telomir Pharmaceuticals ROE % Adjusted to Book Value Calculation

Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-317.66% / 7.73
=-41.09%

Telomir Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-72.90% / 9.03
=-8.07%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -8.07% mean?
Telomir Pharmaceuticals (TELO) has a ROE % Adjusted to Book Value of -8.07% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telomir Pharmaceuticals and its competitors.
Is Telomir Pharmaceuticals' ROE % Adjusted to Book Value too high?
Telomir Pharmaceuticals' current ROE % Adjusted to Book Value is -8.07%. Overall, Telomir Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Telomir Pharmaceuticals' ROE % Adjusted to Book Value compare to MAIA and LONA?
Telomir Pharmaceuticals' ROE % Adjusted to Book Value of -8.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telomir Pharmaceuticals and its competitors. Telomir Pharmaceuticals's current ROE % Adjusted to Book Value is -8.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telomir Pharmaceuticals stock overvalued right now?
Telomir Pharmaceuticals (TELO) has a current ROE % Adjusted to Book Value of -8.07%. The current ROE % Adjusted to Book Value is -8.07%. Telomir Pharmaceuticals' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Telomir Pharmaceuticals (TELO), the current ROE % Adjusted to Book Value is -8.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telomir Pharmaceuticals Business Description

Address 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
14GF Score

Get the complete analysis for TELO

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price